CAS 1253186-56-9 GSK-7975A

GSK-7975A - CAS 1253186-56-9

Catalog number: B0084-475226

Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Molecular Formula:
Molecular Formula	C18H12F5N3O2
Molecular Weight:
Molecular Weight	397.31
COA:
COA	Inquire
Targets:
Targets	Others
Description:
Description	This active molecular is a calcium release-activated calcium modulator (ORAI1) inhibitor. GSK-7975A inhibited toxin-induced activation of ORAI1 and/or activation of Ca(2+) currents after Ca(2+) release in mouse and human pancreatic acinar cells. GSK-7975A may be used for the treatment of pancreatitis in the future.

Ordering Information

Catalog Number	Size	Price	Stock	Quantity
B0084-475226	50 mg	$598	In stock

Bulk Inquiry

Publication citing BOC Sciences Products

1. The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis

2. Quantitative structure-retention relationship modeling of the retention behavior of selected antipsychotic drugs in normal-phase thin-layer chromatography

3. Lipoxin A4 preconditioning attenuates intestinal ischemia reperfusion injury through Keap1/Nrf2 pathway in a lipoxin a4 receptor independent manner

4. Concentration of furfuryl alcohol in fluid milk, dried dairy ingredients, and cultured dairy products

5. Long-Lasting Inhibitory Effects of Distigmine on Recombinant Human Acetylcholinesterase Activity

6. Free Monoterpene Isomer Profiles of Vitis Vinifera L. cv. White Wines

>> More

Purity:
Purity	98%
Appearance:
Appearance	Powder
Synonyms:
Synonyms	GSK-7975A; GSK 7975A; GSK7975A; GSK-7975; GSK 7975; GSK7975. SCHEMBL705705; AOB4124; CPYTVBALBFSXSH-UHFFFAOYSA-N;2,6-difluoro-N-[1-[[4-hydroxy-2-(trifluoromethyl)phenyl]methyl]pyrazol-3-yl]benzamide
Solubility:
Solubility	Soluble in DMSO
Storage:
Storage	-20°C Freezer
MSDS:
MSDS	Inquire
Application:
Application	pancreatitis
Quality Standard:
Quality Standard	In-house standard
Shelf Life:
Shelf Life	2 month in rt, long time

Quantity:
Quantity	Milligrams-Grams
InChIKey:
InChIKey	CPYTVBALBFSXSH-UHFFFAOYSA-N
InChI:
InChI	InChI=1S/C18H12F5N3O2/c19-13-2-1-3-14(20)16(13)17(28)24-15-6-7-26(25-15)9-10-4-5-11(27)8-12(10)18(21,22)23/h1-8,27H,9H2,(H,24,25,28)
Canonical SMILES:
Canonical SMILES	C1=CC(=C(C(=C1)F)C(=O)NC2=NN(C=C2)CC3=C(C=C(C=C3)O)C(F)(F)F)F
Current Developer:
Current Developer	GSK

1.Store-operated calcium entry suppressed the TGF-β1/Smad3 signaling pathway in glomerular mesangial cells.

Chaudhari S;Li W;Wang Y;Jiang H;Ma Y;Davis ME;Zuckerman JE;Ma R Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F729-F739. doi: 10.1152/ajprenal.00483.2016. Epub 2017 Jun 21.

Our previous study demonstrated that the abundance of extracellular matrix proteins was suppressed by store-operated Ca;2+; entry (SOCE) in mesangial cells (MCs). The present study was conducted to investigate the underlying mechanism focused on the transforming growth factor-β1 (TGF-β1)/Smad3 pathway, a critical pathway for ECM expansion in diabetic kidneys. We hypothesized that SOCE suppressed ECM protein expression by inhibiting this pathway in MCs. In cultured human MCs, we observed that TGF-β1 (5 ng/ml for 15 h) significantly increased Smad3 phosphorylation, as evaluated by immunoblot. However, this response was markedly inhibited by thapsigargin (1 µM), a classical activator of store-operated Ca;2+; channels. Consistently, both immunocytochemistry and immunoblot showed that TGF-β1 significantly increased nuclear translocation of Smad3, which was prevented by pretreatment with thapsigargin. Importantly, the thapsigargin effect was reversed by lanthanum (La;3+;; 5 µM) and GSK-7975A (10 µM), both of which are selective blockers of store-operated Ca;2+; channels. Furthermore, knockdown of Orai1, the pore-forming subunit of the store-operated Ca;2+; channels, significantly augmented TGF-β1-induced Smad3 phosphorylation.

2.Ca

Drumm BT;Rembetski BE;Cobine CA;Baker SA;Sergeant GP;Hollywood MA;Thornbury KD;Sanders KM J Physiol. 2018 Apr 15;596(8):1433-1466. doi: 10.1113/JP275719.

KEY POINTS: ;Contraction of urethral smooth muscle cells (USMCs) contributes to urinary continence. Ca;2+; signalling in USMCs was investigated in intact urethral muscles using a genetically encoded Ca;2+; sensor, GCaMP3, expressed selectively in USMCs. USMCs were spontaneously active in situ, firing intracellular Ca;2+; waves that were asynchronous at different sites within cells and between adjacent cells. Spontaneous Ca;2+; waves in USMCs were myogenic but enhanced by adrenergic or purinergic agonists and decreased by nitric oxide. Ca;2+; waves arose from inositol trisphosphate type 1 receptors and ryanodine receptors, and Ca;2+; influx by store-operated calcium entry was required to maintain Ca;2+; release events. Ca;2+; release and development of Ca;2+; waves appear to be the primary source of Ca;2+; for excitation-contraction coupling in the mouse urethra, and no evidence was found that voltage-dependent Ca;2+; entry via L-type or T-type channels was required for responses to α adrenergic responses.;ABSTRACT: ;Urethral smooth muscle cells (USMCs) generate myogenic tone and contribute to urinary continence. Currently, little is known about Ca;2+; signalling in USMCs in situ, and therefore little is known about the source(s) of Ca;2+; required for excitation-contraction coupling.

3.Characterization of selective Calcium-Release Activated Calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparations.

Rice LV;Bax HJ;Russell LJ;Barrett VJ;Walton SE;Deakin AM;Thomson SA;Lucas F;Solari R;House D;Begg M Eur J Pharmacol. 2013 Mar 15;704(1-3):49-57. doi: 10.1016/j.ejphar.2013.02.022. Epub 2013 Feb 27.

Loss of function mutations in the two key proteins which constitute Calcium-Release Activated Calcium (CRAC) channels demonstrate the critical role of this ion channel in immune cell function. The aim of this study was to demonstrate that inhibition of immune cell activation could be achieved with highly selective inhibitors of CRAC channels in vitro using cell preparations from human, rat, mouse and guinea-pig. Two selective small molecule blockers of CRAC channels; GSK-5498A and GSK-7975A were tested to demonstrate their ability to inhibit mediator release from mast cells, and pro-inflammatory cytokine release from T-cells in a variety of species. Both GSK-5498A and GSK-7975A completely inhibited calcium influx through CRAC channels. This led to inhibition of the release of mast cell mediators and T-cell cytokines from multiple human and rat preparations. Mast cells from guinea-pig and mouse preparations were not inhibited by GSK-5498A or GSK-7975A; however cytokine release was fully blocked from T-cells in a mouse preparation. GSK-5498A and GSK-7975A confirm the critical role of CRAC channels in human mast cell and T-cell function, and that inhibition can be achieved in vitro. The rat displays a similar pharmacology to human, promoting this species for future in vivo research with this series of molecules.

Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

Quick Inquiry

Featured Items

Drug Discovery

Chemistry

Life Science